Modulation of Toll-Like Receptor Signalling as a New Therapeutic Principle
2010

Modulating Immune Responses for Better Treatments

Editorial

Author Information

Author(s): Philipp M. Lepper, Martha Triantafilou, Luke A. O'Neill, Natalija Novak, Hermann Wagner, Andrew E. Parker, Kathy Triantafilou

Hypothesis

Can targeting Toll-Like Receptor signaling improve therapeutic interventions for inflammatory disorders?

Conclusion

Targeting Toll-Like Receptors may lead to more specific and effective treatments for various inflammatory diseases.

Supporting Evidence

  • Toll-Like Receptors are involved in various diseases including cancer and autoimmune disorders.
  • Research shows that TLRs can initiate and propagate inflammation.
  • Targeting TLR pathways may lead to more specific treatments for inflammatory disorders.

Takeaway

Scientists are looking at special parts of our immune system to help make better medicines for sicknesses like allergies and infections.

Digital Object Identifier (DOI)

10.1155/2010/705612

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication